

Abe Marcadis, MD

Curriculum Vitae

Palm Beach Research Center
1897 Palm Beach Lakes Blvd.
Suite 120
West Palm Beach, FL 33409
(561) 689-0606

Abe Marcadis MD 12/22/11

LICENSE: State of Florida # ME 9264

EDUCATION

1953-1954	University of Tampa Tampa, Florida Undergraduate School
1954-1956	University of Florida Gainesville, Florida Undergraduate School
1956-1960	University of Miami Miami, Florida Medical School
1960-1961	Jackson Memorial Hospital Miami, Florida Internship
1960-1962	Jackson Memorial Hospital Miami, Florida Medical Residency
1960-1963	Jackson Memorial Hospital Miami, Florida Fellowship, Cardiology

PROFESSIONAL EXPERIENCE

3/06 to Present	Investigator Palm Beach Research Center
8/04 – 3/06	Principal Investigator Baumel Eisner, Boca Raton, Florida

Feb 2002 – May 2004	Investigator Comprehensive NeuroScience, Inc, Boynton Beach, Fl.
1998 – Jan 2002	Principal Investigator ICSL – Clinical Studies, Boynton Beach, Fl.
1995 – 1998	1622 N. Federal Hwy, Lake Worth, Fl Office Practice Affiliated with Columbia/HCA
1964 – 1968, and 1970 – 1995	1622 N. Federal Hwy, Lake Worth, Fl Private Practice

CLINICAL EXPERIENCE

General practice to include but not limited to; Tinea Pedis,
Psoriasis Vulgaris, Lesion Scraping, KOH, Infections Cultures,

MILITARY SERVICE

1968 – 1970	Medical Corp. U.S. Army, Hampton, Virginia
-------------	--

HOSPITAL AFFILIATIONS

Lake Worth General Hospital
Lake Worth, Florida

JFK Medical Center
Atlantis, Florida

Good Samaritan Hospital
West Palm Beach, Florida

PROFESSIONAL MEMBERSHIPS/ORGANIZATIONS

1959 – Present	A-O-A Honorary Medical Fraternity
1964 – Present	Palm Beach Medical Society Florida Medical Society Southern Medical Society American Medical Society
1971 – Present	American College of Physicians

LICENSES/CERTIFICATION

1960 – Present Medical License, State of Florida

1969 Diplomat, American Board of Internal Medicine

RESEARCH TRAINING

December 20, 2011 Protecting Human Research Participants
NIH Office of Extramural Research # 820590

November 30, 2007 Protecting Human Research Participants
NIH Office of Extramural Research

2011 CITI Program GCP Training Ref#: 7033923
2010 CITI Program Refresher Training Ref#: 3473362
2008 CITI Program GCP Training Ref#: 1627197
2007 CITI Program Refresher Training Ref#: 1430477
2006 CITI Program Basic Training Ref#:343946

EDC Trainings: Inform, Medidata, Phoenix, OC-RDC, DataLabs
Pharmaceutical specific EDC programs

RESEARCH EXPERIENCE

1. Experience Documented in a Consumer Trial.
2. Placebo Controlled Study to Investigate the Efficacy and Safety of 20.6 and 10.3mg of xxxx in Preventing Meal Induced Heartburn Following a Provocative Meal.
3. Comparing xxxx 20 mg, xxxx 10 mg and xxxx in Heartburn when Administered 10 Minutes Prior to a Provocative Meal.
4. Effectiveness of Transdermal xxxx for the Protection Against Motion Sickness at Sea.
5. Parallel Group, Dose-Response Study of xxxx in Subjects with Moderate to Severe Psoriasis.
6. Wear Study of a 5 CM2 xxxx Acetate Patch With and Without xxxx Applied to the skin.
7. A Prospective Randomized Open-Label Blinded Endpoint Comparing xxxx and xxxx in Patients with Mild to Moderate Hypertension
8. Placebo Controlled Study to Evaluate the Protective Effects of xxxx in Patients with Non-Insulin Dependent Diabetes and Nephropathy
9. A Multicenter, Randomized, Parallel, Open-Label, Actual Use Study With xxxx, a Lipid Lowering Agent, to Assess Consumer Behavior, Compliance, and Safety in a Simulated OTC-Like and RX-Like Population.
10. Safety and Activity of Three Doses of xxxx Compared to xxxx in the Treatment of Herpes Novartis in Immunocompetent Adults.
11. A Comparative Efficacy and Safety Study of xxx and xxx in Study Subjects With Erosive Esophagitis

12. A Sixteen-Week, Double-Blind and Observer-Blind to Lipid-Values, Randomized, Parallel-Group, Multicenter, Active-Controlled Study to Assess the Efficacy and Safety of xxxx xx mg Administered Once Daily Every Evening at Bedtime in Patients with Hypercholesterolemia.
13. Phase I study to Evaluate Safety, Immunogenicity, and Pharmacokinetics of Subcutaneous Injections of xxxx Human Soluble Tumor Necrosis Factor Type I Receptor in Patients with Rheumatoid Arthritis.
14. Phase III Adjuvant Controlled Study of the Effects of xxx Compares to xxxx Every 12 Weeks on AIDS and HIV Progression-Free Survival in Subjects With HIV Infection and CD4 Lymphocytes Between 300 and 549 Cell/uL Regardless of Concomitant HIV Therapies.
15. A Triple-Blind, Randomized, Parallel, Pilot Study of xxxx Vesus xxxx Treatment Regimens in Patients with Mild to Moderate Essential Hypertension.
16. Evaluation of the Safety and Efficacy of Adding xxxx xxxx (8 to 16 mg) to xxxx in the Treatment of Patients with Severe (JNC-V) Hypertension: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Design Study with an Open-Label, Long Term Extension.
17. Multinational, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to compare xxxx 80 mg o.d. Titrated to 160 mg o.d. with xxxx 50 mg o.d. Titrated to 100 mg o.d. in Patients with Mild to Moderate Essential Hypertension.
18. A Double-Blind, Randomized, Stratified, Parallel-Group Study to Assess the Incidence of PUBs During Chronic Treatment with xxx or xxx in Patients with Rheumatoid Arthritis.
19. A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of a xxx Formulation of Molecular Iodine for the Treatment of Moderate or Severe Symptomatic Fibrocystic Breast Disease in Otherwise Healthy, Euthyroid, Premenopausal Women.
20. A Multicenter, Open-Label Long Term Safety Study of xxxx in Subjects with Healed Erosive Esophagitis.
21. A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing Two 12 Hour xxxx Formulations for the Treatment of Patients with Moderate to Severe Chronic Pain.
22. A Two-Week, Double-Blind, Placebo-Controlled Trial of the Effects of xxxx 20, 50, and 100 mg BID on Cognitive Tests in Depressed Geriatric Patients.
23. A Multicenter, Double-Blind, Double-Dummy, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of xxxx (3.75, 7.5, 15 mg) with Placebo in Patients with Osteoarthritis of the Knee or Hip; and xxxx (100 mg) as an Active Control to Assess Trial Sensitivity.
24. A Multicenter, Double-Blind, Double-Dummy, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of xxxx (7.5, 15, and 22.5 mg) with Placebo in Patients with Rheumatoid Arthritis; and with xxxx (150 mg) as an Active Control to Assess Trial Sensitivity.
25. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate xxxx in Patients with Probable Alzheimer's Disease of Mild to Moderate Severity.

26. Phase II Double-Blind, Placebo-Controlled, 4-Week Multiple Dose Evaluation of xxxx for its Safety, Toleration, and Efficacy for Increasing xxxx in Older Normal Men and Women.
27. A Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study of the Effects of xxxx and xxxx in Non-Insulin Dependent Diabetic Patients.
28. A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of xxxx in Patients with Alzheimer's Disease.
29. An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of xxxx in Patients with Mild to Moderate Alzheimer's Disease.
30. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Determine the Efficacy and Safety of xxxx in the Treatment of Osteoporosis in Elderly Women.
31. A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of xxxx Following Four-Week, Step-Wise Dose Escalations in Patients with Probable Alzheimer's Disease.
32. A Multicenter, Double-Blind, Randomized Study to Determine Efficacy in the Relief of Hot Flashes in Women Receiving Transdermal xxxx Compared to Oral Conjugated Estrogens.
33. A Multicenter, Double-Blind, Randomized Comparison of Continuous Oral xxxx Combinations and Continuous Oral xxxx, Examining the Effect on the Endometrium, Symptoms and Bleeding Patterns in Postmenopausal Women.
34. A Multicenter, Double-Blind, Randomized Study of Continuous Transdermal xxxx Combinations, Compared to Continuous Transdermal xxxx, to Examine the Safety and Effect on the Endometrium, Symptoms and Bleeding Patterns in Postmenopausal Women.
35. Safety and Efficacy of Fixed Combination xxxx Products as First Line Therapy in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise.
36. A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of xxxx Oral Dose Form Administered Either Once or Twice a Day in Patients with Type II Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise.
37. A 30-Week, Open-Label Evaluation of xxxx in Patients with Dementia Associated with Cerebrovascular Disease.
38. A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of xxxx in Patients with Dementia Associated with Cerebrovascular Disease.
39. The Comparative Efficacy of xxxx, xxxx, and xxxx for Cognition in Schizophrenia.
40. An Active Comparator and Placebo-Controlled, Parallel-Group, 6-Week Double-Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Efficacy, Safety, and Tolerability of xxxx in Patients Aged 80 and Over with Osteoarthritis of the Knee or Hip.

41. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Effect of xxxx on Insulin and Ovarian Androgen Production in Obese Women with Polycystic Ovary Syndrome (PCOS).
42. A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of xxxx in Patients with Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.
43. A Multicenter, Double-Blind, Randomized, Parallel-Group, Fixed-Dose Study to Prospectively Evaluate the Efficacy, Safety, and Tolerability of xxxx monotherapy, Compared to xxxx monotherapy in Patients with Type II Diabetes Mellitus Inadequately Controlled With Diet.
44. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of xxxx in the Treatment of Moderate to Severe Vasomotor Symptoms and Atrophic Conditions Associated with Menopause.
45. An Open-Label, Non-Comparative, Multicenter Study to Evaluate Contraceptive Efficacy, Cycle Control and Safety of an One-Compartment xxxx Vaginal Ring.
46. A Randomized, Double-Blind, Active-and-Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Safety and Protective Effect on the Endometrium of 4 Dosage Combinations of xxxx Plus xxxx.
47. A Multicenter, Randomized, Open-Label, Comparative Study of the Safety, Toleration, and Efficacy of Oral xxxx For Long-Term Treatment of Subjects with Acute Migraine.
48. An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of xxxx in Elderly Patients with DSM-IV Major Depression.
49. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of xxxx in Patients with Essential Hypertension.
50. An Open-Label, Six Month Extension of xxxx to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 through 6 mg BID (2-12 mg/day) xxxx in Outpatients with Probable Alzheimer's Disease.
51. Evaluation of the Antihypertensive Efficacy of xxxx in Comparison to xxxx: A Multicenter, Double-Blind, Randomized, Parallel-Group, Forced-Titration Study.
52. A Double-Blind, Placebo-Controlled, Parallel-Group Assessment of the Safety and Efficacy of Two Doses of the xxxx Transdermal System (10 mg and 20 mg) in Patients with Major Depression.
53. Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of xxxx, xxxx, and Placebo with an Open-Label Extension in the Treatment of Osteoarthritis of the Knee and/or Hip.
54. Multicenter, Randomized, Double-Blind, xxxx Controlled Study of the Efficacy and Safety of xxxx in Subjects with Major Depressive Disorder Who are at Least 65 Years of Age.
55. A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled Trial in Patients with Essential Hypertension to Compare the Effects of xxxx 80 and 160 mg, With or Without the Addition of xxxx, on Cardiovascular Morbidity and Mortality.
56. A Comparative Trial of xxxx, xxxx, and xxxx in Early Postmenopausal Women: A Randomized, Open-Label, Multicenter Study.

57. An Open-Label Study to Assess the Safety of the xxxx Transdermal System in Patients with Major Depression.
58. A Multicenter, Randomized, Double-Dummy, Parallel-Group Study of xxxx (xxxx oral extended release capsules) in Patients with Chronic, Moderate, and Severe Pain.
59. A Safety and Pharmacokinetic Study of xxxx and xxxx in Parkinson's Disease (PD) Patients Compared to Healthy Volunteers Administered xxxx Alone.
60. A Multicenter, Non-Randomized, Open-Extension Study of xxxx (xxxx oral extended release capsules) in Patients with Chronic, Moderate, and Severe Pain Who Have Completed a Prior xxxx Clinical Trial.
61. A One-Year, Randomized, Placebo-and-Active-Comparator-Controlled, Parallel-Group, Double-Blind, Two-Part Study to Assess the Safety and Efficacy of xxxx Versus xxxx in Patients with Osteoarthritis.
62. For a Phase II Study of xxxx and xxxx with xxxx Support in Patients with Previously Untreated, and Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia.
63. An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of xxxx (xxxx) in Patients with Chronic Low Back Pain.
64. Safety, Efficacy, and Impact on Quality of Life Long-Term Administration of xxxx (xxxx) in Patients with Chronic Low Back Pain.
65. A Double-Blind, Placebo and xxxx-Controlled, Multicenter Study Evaluating the Efficacy and Safety of xxxx in Patients with Major Depressive Disorder.
66. A Phase III, Double-Blind, Efficacy and Safety Study of One Dose of xxxx (10 mg) Compared to Placebo in Subjects with Primary Hypercholesterolemia.
67. A Multicenter, Randomized, Controlled Clinical Trial Comparing the Safety and Efficacy of xxxx to xxxx 3.75 mg in Women with Endometriosis-Associated Pain.
68. A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of xxxx for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and its Impact on the Quality of Life in These Patients.
69. A 24-Week, Randomized, Double-Blind, Multicenter, Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of xxxx and xxxx in the Treatment of High Risk Hypercholesterolemic Subjects.
70. A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of xxxx (5,10, 20, 40, and 80 mg) in the Treatment of Subjects with Hypertriglyceridemia.
71. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of 30 mg and 90 mg xxxx Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder.
72. An Open-Label Study of the Safety, Tolerability, and Efficacy of up to 90 mg xxxx Extended Release in Patients with Generalized Anxiety Disorder.
73. A Multicenter, Randomized, Double-Blind, Active-Control Trial to Evaluate the Safety and Efficacy of xxxx as First Line Therapy in Patients with Type II

- Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise.
74. Ninety Day Safety Study of xxxx in Male and Female Parkinson's Patients on xxxx + xxxx.
 75. An Innovative Approach to the Treatment of Post-Herpetic Neuralgia: An Open-Label Study of xxxx.
 76. A Double-Blind, Randomized, Placebo-Controlled Clinical Trial in Postmenopausal Women to Demonstrate the Efficacy of Intravaginal Rings Releasing xxxx with Respect to Postmenopausal Vasomotor Symptoms.
 77. Xxxx Versus Placebo and xxxx in the Acute Treatment of Major Depression.
 78. A Multicenter, Double-Blind, Placebo-Controlled Study of the Tolerability and Effect of xxxx in Parkinson's subjects with End-of-Dose Wearing off Symptoms Occurring no Earlier than 4 Hours After Their Most Recent xxxx Dose.
 79. A Prospective, Double-Blind, Randomized, Parallel Efficacy Study of a xxxx Treatment Regimen Versus Placebo in the Treatment of Patients with Isolated Systolic Hypertension.
 80. A Placebo-Controlled, Parallel-Group, 4-Week Trial Conducted Under Double-Blind Conditions to Assess the Efficacy and Safety of xxxx in Patients with Chronic Low Back Pain.
 81. Evaluation of Daily Dose of xxxx 7.5 mg Compared to Placebo in the Treatment of Symptomatic Postmenopausal Women.
 82. Xxxx, Placebo, and xxxx Comparison in Patients with Major Depressive Disorder.
 83. A Single-Dose, Double-Blind, Safety and Efficacy of xxxx, xxxx, and xxxx in Subjects with Acute Migraine Attacks.
 84. Long-Term, Open-Label, Safety and Tolerability Study of xxxx in Subjects with Primary Hypercholesterolemia.
 85. Randomized, Multicenter, Multi-Dose, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Sustained-Release xxxx to Placebo in the Treatment of Pain Associated with Osteoarthritis.
 86. A Multicenter, Comparison of Continuous Transdermal xxxx Combinations, Examining the Effect on the Endometrium, and Bleeding Patterns in Previously Randomized Postmenopausal Women Who Have Completed 13 Cycles (1 Year) of xxxx Hormone Replacement Therapy.
 87. A Comparative Efficacy Study of xxxx (40 mg QD) and xxxx (30 mg QD) in Patients with Erosive Esophagitis.
 88. An Open-Label, Multinational, Multicenter, Extension Trial to Assess the Long-Term Safety and Efficacy of xxxx in Subjects in the xxxx Clinical Trial Program.
 89. Xxxx Cardiovascular Treatment Assessment Versus xxxx.
 90. A Multicenter, Randomized, Double-Blind, Active-Control Trial to Compare the Safety and Efficacy of a New Formulation of xxxx Tablets (500/1.25 mg) to xxxx as First Line Therapy in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise.
 91. A Double-Blind, Randomized Study to Evaluate the Effects of Fixed Combination xxxx Therapy in Subjects with Type II Diabetes Mellitus Who Have

- Inadequate Glycemic Control on Half-Maximum to Maximum of the Labeled Doses of xxxx Monotherapy.
92. Patient Treatment Preference and Satisfaction with Migraine Headache Therapy: xxxx Tablets Versus Current xxxx Therapy.
 93. A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial of 2 Doses of xxxx (200 and 400 mg QD) in Patients with Rheumatoid Arthritis Using xxxx (200 mg BID) as a Comparator.
 94. A Randomized, Open-Label, Comparative, Multicenter Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic xxxx containing 200 mg xxxx and 20 mg xxxx, Compared to a xxxx Containing 100 mg xxxx and 20 mg xxxx.
 95. Pharmacogenomics Blood Sampling Protocol.
 96. A Six-Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of xxxx (0.5, 3, and 10 mg) and xxxx in Subjects with Major Depressive Disorder.
 97. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of xxxx in Outpatients with Generalized Anxiety Disorder.
 98. Open-Label xxxx Continuation Therapy in Patients with Major Depression Disorder.
 99. A Randomized, Double-Blind, xxxx and Placebo-Controlled Evaluation of xxxx and Over-Encapsulated xxxx, Alone and in Combination in the Acute Treatment of a Migraine Attack.
 100. A Multicenter, Multinational, Open-Label Extension Study of Oral xxxx for the Treatment of Opioid-Induced Constipation in Patients with Chronic, Non-Malignant or Malignant Pain.
 101. Open-Label, Multicenter, Multi-Dose Study Evaluating the Long-Term Efficacy and Safety of xxxx SR (Titrated Dose) in the Treatment of Pain Associated with Osteoarthritis.
 102. A Double-Blind, Placebo-and xxxx-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of xxxx in Outpatients with Major Depressive Disorder.
 103. A Double-Blind, Placebo Controlled, 3-Arm Fixed Dose Study of xxxx CR Continuous Treatment (12.5 mg and 25 mg/day) for Premenstrual Dysphoric Disorder.
 104. A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of xxxx in Non-Constipated Patients with Established Irritable Bowel Syndrome.
 105. A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of xxxx Tablets to xxxx Plus xxxx Therapy in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control with xxxx Monotherapy.
 106. A Randomized, Comparator, Controlled, Double-Blind Study of the Liver Safety of xxxx Versus xxxx with xxxx and Insulin as Part of Step Therapy in Subjects with Type II (Non-Insulin Dependent) Diabetes.

107. A Phase IIB, Six-Week, Double-Blind, Placebo-and xxxx-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of xxxx (0.5, 3, and 10 mg) and xxxx in Subjects with Major Depressive Disorder.
108. A Six-Week, Double-Blind, Placebo-Controlled, Fixed Dose, Extension Study of xxxx (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies xxxx, xxxx, or xxxx.
109. A Phase II, Randomized, Double-Blind, Vehicle-Controlled, Dose Frequency Response Study of Topical xxxx Gel Applied to Anogenital Herpes Lesions Once, Twice, or Three Times Per Week for One Recurrence to Prevent Future Recurrences.
110. A Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Trial to Study the Efficacy, Safety, and Steady State Pharmacokinetics of xxxx (Dose Levels: 80 mg, 120 mg, 160 mg, and 640 mg) in Patients with Essential Hypertension.
111. Antihypertensive Efficacy of Adding xxxx to xxxx in Comparison to Up-Titration of xxxx: A Multicenter Trial Using xxxx vs xxxx to Evaluate the Effects on Lowering Blood Pressure.
112. A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Severe Alzheimer's Disease Followed by a 12-Week Open-Label Extension.
113. Placebo-Controlled Evaluation of xxxx in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled Release Formulations.
114. A Placebo-Controlled, Dose-Titration Efficacy and Tolerability Study of xxxx in Patients with Probable Alzheimer's Disease.
115. A Randomized, 26-Week, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of xxxx in the Treatment of Dementia Secondary to Cerebrovascular Disease.
116. A Randomized, Double-Blind, Safety and Efficacy Pilot Study of xxxx Versus xxxx as First-Line Antihypertensive Therapy in Patients with Type II Diabetes Mellitus and Hypertension.
117. Multicenter, Randomized, Double-Blind, Active-Controlled Trial to Compare the Efficacy and Safety of 104 Weeks of xxxx Plus xxxx vs xxxx Plus xxxx in Drug Naïve Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise.
118. A 52-Week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy, Tolerability, and Safety of 3-12 mg/day of xxxx Capsules in Patients with Probable Vascular Dementia.
119. A 13-Week, International, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Assessing the Safety and Efficacy of 2 Doses xxxx (200 mg and 400 mg OD) in Patients with Knee Primary Osteoarthritis, Using xxxx (200 mg OD) as a Comparator.
120. A 26-Week, International, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Endoscopic Study of Gasroduodenal Effects of xxxx (400 mg and 800 mg) in Patients with Rheumatoid Arthritis Using xxxx (800 mg TID) and xxxx (200 mg BID) as Comparators.

121. A Phase IIB, Seven-Week, Double-Blind, Placebo-and xxxx-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Oral xxxx in Outpatients with Major Depressive Disorder and Associated Somatic Symptoms.
122. Preliminary Efficacy Study in Pre-Menopausal Women with Normal or Impaired Sexual Function Due to Acquired Arousal and/or Orgasm Disorder Comparing xxxx 0.1 mg to Placebo: Double-Blind with 8-Week Home Treatment Phase.
123. Phase III Contraception Study of xxxx Subcutaneous Injection in Women of Childbearing Potential in the Americas (Including a Bone Mineral Density {BMD} Substudy Comparing the Effects of xxxx and xxxx) Also Including a Return of Ovulation Substudy.
124. Phase III Study of xxxx Subcutaneous Injection in Women with Endometriosis in the US and Canada.
125. Effects of Oral xxxx on Lipoproteins in Subjects with Type II Diabetes Mellitus Who are Receiving Statin Therapy.
126. A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of xxxx in the Treatment of High-Grade Squamous Intra-Epithelial Lesions of the Uterine Cervix.
127. Prospective, Randomized, Double-Blind, Multicenter, Comparative Trial to Evaluate the Efficacy and Safety of xxxx Once-Daily (QD) Modified Release Tablets 1000 mg Versus Conventional xxxx 500 mg Tablets BID in the 7-14 Day Treatment of Patients with Complicated Urinary Tract Infections (cUTI) or Acute Uncomplicated Pyelonephritis.
128. Open-Label Pilot Study Assessing the Efficacy and Safety of New Formulations of xxxx in the Treatment of Low Back Pain.
129. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Three Doses of xxxx (0.3 mg, 0.45 mg, and 0.625 mg Modified Release Tablets) Compared with Placebo in Hysterectomized Postmenopausal Women for the Prevention of Osteoporosis.
130. Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Comparison of the Efficacy and Safety of Extended Release xxxx and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip.
131. An Open-Label Extension Trial to Assess the Long-Term Safety of a Controlled Release Formulation of xxxx in the Treatment of Alzheimer's Dementia.
132. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Determine Efficacy in the Relief of Hot Flashes in Women Receiving Oral xxxx Tablets.
133. A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study of the Effects of xxxx on Safety and Efficacy in Patients with Mild to Moderate Hypertension.
134. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Comparative Trial to Assess the Endometrial Histological Profile Following Treatment with xxxx Versus xxxx in Postmenopausal Women.
135. A Seven-Week, Double-Blind, Extension of xxxx: A Phase IIB, Seven-Week, Double-Blind, Placebo-and xxxx-Controlled, Multicenter Study to

- Evaluate the Safety and Efficacy of Oral xxxx in Outpatients with Major Depressive Disorder and Associated Somatic Symptoms.
136. A Double-Blind, Placebo-Controlled, Parallel-Group Designed Study of Two Doses of xxxx Versus Placebo for the Treatment of Sexual Dysfunction (Hyperactive Desire) in Postmenopausal Women.
 137. A Double-Blind, Placebo-Controlled, Parallel-Group Design Study of Two Doses of xxxx Versus Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.
 138. A Double-Blind, Randomized, Parallel-Group Study of xxxx 10 mg QD Versus Placebo in the Management of Acute Urinary Retention in Patients with a First Episode Due to BPH.
 139. A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of xxxx in Patients with Type II Diabetes.
 140. A Phase II Study on Analgesic Efficacy, Safety, and Tolerability of xxxx: A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Multicenter Study Comparing xxxx with xxxx and with xxxx in Subjects with Osteoarthritis of the Knee.
 141. Analgesic Efficacy of xxxx Versus xxxx in Opioid Naïve and Opioid Experienced, Chronic Pain Patients.
 142. Phase II Dose-Ranging Study of xxxx in Patients with Chronic Pain Due to Osteoarthritis.
 143. An Open-Label Extension Trial to Assess the Safety of xxxx in the Treatment of Vascular Dementia.
 144. A Randomized, Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multiple-Dose, Phase IIB Study to Assess the Efficacy and Safety of xxxx SR (25 mg, 50 mg, 100 mg; twice daily) in Comparison to xxxx CR 20 mg twice daily in Patients with Chronic Hip or Knee-Joint Osteoarthritis.
 145. Xxxx Versus Placebo in the Prevention of Relapse of Major Depressive Disorder.
 146. A Randomized, Double-Blind, Placebo-Controlled Study Evaluating xxxx Extended Release (1950 mg/day and 390 mg/day) in the Treatment of Osteoarthritis of the Hip or Knee.
 147. A Multicenter, Double-Blind, Randomized, Parallel-Group, 28-Week Study to Evaluate the Efficacy and Safety of xxxx and xxxx Co-Administration Versus xxxx in Patients with Hypercholesterolemia.
 148. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of a Modified Release Formulation of xxxx in Adult Patients with Primary Insomnia.
 149. A Multicenter, Prospective, Randomized, Double-Blinded, Parallel-Group Study Comparing the Effects of xxxx (5/20 mg) to xxxx (5 mg) and xxxx (20 mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension.
 150. Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Two Week Comparison Study of the Efficacy and Tolerability of xxxx 10 mg QD

- and xxxx 25 mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee.
151. A Double-Blind, Randomized, Placebo-and Active-Controlled Safety and Efficacy Study of xxxx Estrogen Combinations in Postmenopausal Women.
 152. Xxxx 30 mg and 60 mg Once Daily Versus Placebo in Generalized Anxiety Disorder. A Randomized, Double-Blind, Placebo-and xxxx-Controlled, Fixed-Dose, Parallel-Group, Multicenter Study of 10 Weeks (Including a 2-Week Single-Blind Placebo Period).
 153. Xxxx 60 mg (or 30 mg) Once Daily in the Treatment of Generalized Anxiety Disorder. An Open-Label, Multicenter Safety Study of 5 Months, Including a 1-Month Drug-Free Follow-Up Period. Follow-Up to Studies xxxx and xxxx.
 154. A Phase III, Multinational, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of xxxx (300 mg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder on Concurrent Oral Hormone Replacement Therapy.
 155. A Phase III, Multinational, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of xxxx (300 mg/day) for 24-Weeks and Safety for a Further 28-Week, Open-Label Period in Women with Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy Who Have Undergone Hysterectomy and Bilateral Oophorectomy.
 156. A Four-Week, Double-Blind, Placebo and Active-Controlled, Dose-Ranging Study of xxxx, 3 Doses (5, 15, 50 mg per day) and xxxx (3 mg/day) in Outpatients with Generalized Anxiety Disorder (GAD).
 157. A Phase III, Open-Label Study of the Safety, Tolerability, and Efficacy of the xxxx (20 mg/20cm², 30 mg/30cm², 40 mg/40cm²) in Elderly Subjects with Major Depression.
 158. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy Trial of the Use of xxxx in the Treatment of Patients with Bipolar Depression.
 159. A Pilot Study of the Effect of Hormone Replacement Therapy in Recently Postmenopausal Women with Subjective Cognitive Complaints.
 160. The Efficacy, Onset of Effect, and Safety of xxxx Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score.
 161. A Double-Blind, Placebo-Controlled Trial of xxxx in Atypical Depression.
 162. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Factorial Study of xxxx Extended-Release Tablets (xxxx), xxxx and their Combination in Patients with Essential Hypertension.
 163. A Randomized, Double-Blind, Placebo-Controlled Study of Oral xxxx (6.25 mg, 12.5, and 25 mg) in the Acute Treatment of Migraine in Adolescents.
 164. An Evaluation of xxxx, 0.5% Gel in Female Sexual Dysfunction Due to Androgen Insufficiency.

165. A Phase IIB, Multicenter, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of xxxx Following a Run-In of xxxx Extended Regimen Oral Contraceptive Therapy.
166. An Open-Label Effectiveness and Safety Study of xxxx Extended Release in Opioid-Naïve Patients with Chronic Pain.
167. Efficacy and Safety Study of xxxx Postmenopausal Women.
168. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD, and 1 mg BID of xxxx in Female Subjects with Severe Diarrhea-Predominant IBS Who Have Failed Conventional Therapy.
169. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control Clinical Evaluation of Insulin Plus xxxx (2 mg and 4 mg) Compared to Insulin Plus Placebo for 24-Weeks in Subjects with Type II Diabetes Mellitus Who are Inadequately Controlled on Insulin.
170. Study B- A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of xxxx Monotherapy in Patients with Type II Diabetes Mellitus.
171. A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of xxxx in Decreasing the Risk of Prostate Cancer (ViP Study).
172. A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Safety and Efficacy of xxxx Extended-Release and xxxx in Subjects with Non-Malignant Pain.
173. A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Comparative study of xxxx and Open-Label xxxx, in Patients with Type II Diabetes.
174. A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of xxxx 9 mg and 30 mg in Patients with Diabetic Polyneuropathy.
175. A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of xxxx 30 mg QD and xxxx 500 mg BID Versus xxxx 200 mg QD in Risk Reduction of Non-Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking a Low Dose Aspirin.
176. A Phase III, Randomized, Multicenter, xxxx-and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral xxxx in Subjects with Gout.
177. A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of xxxx 90 MCG and xxxx 20 UG in a Continuous Daily Regimen for Oral Contraception.
178. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4-Weeks of Treatment with xxxx 20 mg QD to Placebo QD for the Resolution of Upper Abdominal Pain in Patients with Symptomatic Gastro esophageal Reflux Disease (sGERD).
179. An Open-Label, Long-Term Effectiveness and Safety Study of xxxx and Extended Release Tablets in Patients with Cancer or Neuropathic Pain.
180. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Evaluating Efficacy, Safety, and Tolerability of Once-

- Daily Oral xxxx (40-60 mg) Versus Placebo in Subjects with Major Depressive Disorder over an Eight-Week Treatment Period.
181. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of xxxx 25 mg in Slowing the Progression of Alzheimer's Disease.
 182. A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed-Dose of xxxx (700 mg/day) Versus Placebo and xxxx (20 mg/day) in Patients with a Recurrent Major Depressive Episode.
 183. A Randomized, Multicenter, Double-Blind, Single-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of xxxx Tablets 220 mg with Arthritis Pain Relief xxxx Caplets 650 mg for the Treatment of Primary Dysmenorrhea.
 184. A 12-Week, Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of xxxx in African American Patients with Mild to Moderate Alzheimer's Disease.
 185. A Multicenter, Double-Blinded, Controlled, Randomized Study to Compare the Efficacy in Relief of Hot Flushes in Women Receiving Oral xxxx Tablets, Oral xxxx Tablets or Oral xxxx.
 186. A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of xxxx 20 mg/day, 300 mg/day, 400 mg/day Compared to Placebo in Subjects with Painful Diabetic Neuropathy.
 187. A Phase III, Open-Label Study to Assess the Long-Term Safety of Oral xxxx in Subjects with Gout.
 188. A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of xxxx in Subjects with Mild Cognitive.
 189. A Randomized, Double-Blind, Controlled Study of xxxx for the Treatment of Postherpetic Neuralgia.
 190. A Study to Assess the Safety, Tolerability, and Efficacy of Oral xxxx Administered for Ninety Days in Subjects with Probable Alzheimer's Disease.
 191. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of xxxx to Slow the Progression of Alzheimer's Disease.
 192. A Phase II, Double-Blind, Randomized, Parallel-Group Study of the Comparative Efficacy and Safety of xxxx Tablets (5 and 20 mg Twice Daily) Versus Placebo in Adults with Mild to Moderate Alzheimer's Disease.
 193. A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx Patients with Severe Alzheimer's Disease Followed by a 12-Week Open-Label Extension Period.
 194. A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety, and Tolerability of xxxx in Patients with Dementia Associated with Cerebrovascular Disease.
 195. An Open-Labels, Multicenter, One-Year Extension of the Evaluation of xxxx in Patients with Dementia Associated with Cerebrovascular Disease.
 196. A 51-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of xxxx Subjects with Mild Cognitive Impairment.

197. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Moderate to Severe Dementia of the Alzheimer's Type.
198. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Moderate to Severe Dementia of the Alzheimer's Type.
199. A Long-Term Extension Study Evaluating the Safety and Tolerability of Four xxxx Dosing Regimens of Patients with Moderate to Severe Dementia of the Alzheimer's Type.
200. A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of xxxx in Patients with Mild to Moderate Dementia of the Alzheimer's Type.
201. A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Efficacy and Safety of xxxx in Comparison to xxxx in Patients with Painful Diabetic Neuropathy.
202. A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Efficacy and Safety of xxxx in Comparison to xxxx in Patients with Postherpetic Neuralgia.
203. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Moderate to Severe Dementia of the Alzheimer's Type with Behavioral Disturbances.
204. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Moderate to Severe Dementia of the Alzheimer's Disease.
205. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of xxxx 25 mg in Patients with Mild to Moderate Alzheimer's Disease.
206. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of xxxx 25 mg in Slowing the Progression of Alzheimer's Disease.
207. A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups, Efficacy and Safety Extension Study of xxxx 15 mg and 10 mg in the Treatment of Adult Outpatients with Primary Insomnia.
208. Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with xxxx on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's type.
209. A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel-Group Evaluation of the Efficacy, Safety, and Tolerability of the Once-Daily xxxx Patch Formulation in Patients with Probable Alzheimer's Disease.
210. A Double-Blind, Phase II, Safety and Efficacy Evaluation of xxxx in Patients with Mild to Moderate Alzheimer's Disease.
211. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of xxxx in Subjects with Mild to Moderate Dementia of the Alzheimer's Type.

212. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of xxxx in Patients with Mild to Moderate Alzheimer's Disease.
213. A Dose-Ranging, Placebo-Controlled Study of xxxx at the Doses of 0.5 mg, 2 mg, and 8 mg for 12-Weeks in Patients with Mild to Moderate Alzheimer's Disease.
214. Evaluation of the Hypnotic Properties of xxxx 12.5 mg and xxxx 10 mg Marketed Product Compared to Placebo in Patients with Primary Insomnia. A Double-Blind, Randomized, Placebo-Controlled Three Way Crossover Study.
215. A Double-Blind, Randomized, Placebo-Controlled, Phase II-A, Multiple-Dose, Multicenter Study in Patients with Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally Administered xxxx.
216. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 16-Week, Multicenter Trial Evaluating the Efficacy and Safety of xxxx 500 mg Tablets in BID Administration (Daily Dose Ranging from 1000 mg to 3000 mg), in Adults (Greater than or equal to 18 Years of Age) Suffering from Postherpetic Neuralgia.
217. A Double-Blind, Placebo-Controlled Study of xxxx Treatment of Alzheimer's Disease.
218. A Double-Blind, Placebo-Controlled Study of xxxx Treatment of Alzheimer's Disease in Men.
219. An Open-Label Extension of a Double-Blind, Placebo-Controlled Study of xxxx in the Treatment of Alzheimer's Disease in Men.
220. Open-Label Extension of Double-Blind, Placebo-Controlled Study of xxxx in the Treatment of Alzheimer's Disease.
221. A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending, Fixed-Doses of xxxx in Subjects with Mild to Moderate Alzheimer's Disease.
222. Investigational Study of the Effects of xxxx on the Levels and Ratios of the Fatty Acids xxxx acid, and xxxx acid in Cystic Fibrosis Patients.
223. A Randomized, Placebo-Controlled, Double-Blind Study of xxxx for the Treatment of Chronic Constipation.
224. A Randomized, Controlled, 14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe-Dose of xxx in a Metered-Dose Inhaler in the Treating Patients with Chronic Obstructive Pulmonary Disease.
225. Do xxx Treatments Temporarily Relieve Musculoskeletal Pains Associated with Osteoarthritis of One or Both Hips?
226. Tolerability of xxxx Compared to xxxx in Patients with Mild-Moderate Hypertension on xxxx.
227. A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of xxxx of Subjects with Fibromyalgia.
228. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous xxxx for the Treatment of Opioid-Induced Constipation in Subjects with Chronic Non-Malignant Pain.

229. A 16-Week, Phase I, Multicenter, Double-Blind, Randomized, xxxx and xxxx-Controlled, Parallel-Group Pharmacological Study, to Assess the Effect of xxxx (375 mg and 750 mg BID) Compared to xxxx Doses of xxxx (250 mg and 500 mg, BID) and to xxxx (600 mg, TID) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients with Controlled Essential Hypertension.
230. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study of xxxx in Adult Migraineurs for a Single Migraine Followed by Open-Label Extensions to 26/52 Weeks.
231. An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at xxxx Among xxxx-Treated Outpatients with Depression.
232. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of xxx in Patients with Osteoarthritis of the Knee.
233. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of xxxx in Patients with Osteoarthritis of the Hip.
234. A Phase III, Randomized, Double-Blind, Placebo and xxxx Controlled Multicenter Study of the Analgesic Efficacy and Safety of xxxx in Patients with Osteoarthritis of the Knee.
235. A Phase III, Multicenter, Randomized, Long-Term Study of the Safety of xxxx in Patients with Osteoarthritis of the Knee or Hip.
236. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of xxx (xxxx Topical Cream 10%) in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury.
237. A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of xxxx Extended-Release 50 mg Versus xxxx 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastro esophageal Reflux Disease (GERD).
238. A Phase III, Double-Blind, Randomized, Efficacy and Safety Study of the xxxx Plus xxxx Fixed-Dose Combination Compared With xxxx and xxxx Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension.
239. Efficacy and Safety of xxxx in the Treatment of Severe Chronic Hand Exzema Refractory to Topical Therapy.
240. A Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of xxxx Administered Subcutaneously for the Treatment of an Acute Gout Flare.
241. A Phase II, Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of xxxx Compared to Placebo in Subjects with Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia.
242. A Randomized, Double-Blind, Sham Control Clinical Trial to Evaluate the Safety and Efficacy of the xxx for the Treatment of Androgenetic Alopecia in Males.
243. Efficacy and safety of new xxxx 6 mg and 9 mg extended release tablet formulations in patients with mild or moderate, active ulcerative colitis. A

multicenter, randomized, double-blind, double dummy comparative study versus placebo, with an additional reference arm evaluating xxxx 2400 mg.

AC# 4665011

STATE OF FLORIDA
DEPARTMENT OF HEALTH
DIVISION OF MEDICAL QUALITY ASSURANCE

DATE	LICENSE NO.	CONTROL NO.
11/19/2011	ME 9264	364310



The **MEDICAL DOCTOR** named below has met all requirements of the laws and rules of the state of Florida.
 Expiration Date: **JANUARY 31, 2014**
ABE MARCADIS
 1897 PALM BEACH LAKES BLVD
 SUITE 120
 WEST PALM BCH, FL 33409

Rick Scott
 GOVERNOR

Kimberly Berfield
 DEPUTY SECRETARY

DISPLAY IF REQUIRED BY LAW

STATE OF FLORIDA
 DEPARTMENT OF HEALTH
 DIVISION OF MEDICAL QUALITY ASSURANCE
 AC# 4665011

DATE	LICENSE NO.	CONTROL NO.
11/19/2011	ME 9264	364310



The **MEDICAL DOCTOR** named below has met all requirements of the laws and rules of the state of Florida.
 Expiration Date: **JANUARY 31, 2014**
ABE MARCADIS

LICENSEE SIGNATURE